These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 21914505)

  • 21. Efficacy and tolerability of lanthanum carbonate in treatment of hyperphosphatemia patients receiving dialysis--a systematic review and meta-analysis of randomized controlled trials.
    Huang W; Liu J; Tang Y; Gao X; Di B; Zhang F
    Curr Med Res Opin; 2014 Jan; 30(1):99-108. PubMed ID: 24063635
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sevelamer is cost-saving vs. calcium carbonate in non-dialysis-dependent CKD patients in italy: a patient-level cost-effectiveness analysis of the INDEPENDENT study.
    Ruggeri M; Cipriani F; Bellasi A; Russo D; Di Iorio B
    Blood Purif; 2014; 37(4):316-24. PubMed ID: 25171148
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multicenter study on the long-term (3-year) efficacy of lanthanum carbonate in dialysis patients.
    Ando R; Yama S; Ohnishi T; Iwamoto S; Kimura H; Chida Y; Ishida Y; Yamada K; Inagaki Y; Takayama M; Tachibana K; Kikuchi K; Inoue A; Ohtsuka M
    Ther Apher Dial; 2014 Jun; 18 Suppl 1():2-8. PubMed ID: 24953759
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and effectiveness of lanthanum carbonate for hyperphosphatemia in chronic kidney disease (CKD) patients: a meta-analysis.
    Zhao L; Liu A; Xu G
    Ren Fail; 2021 Dec; 43(1):1378-1393. PubMed ID: 34602015
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Lanthanum carbonate and new phosphate binders in patients with chronic kidney disease].
    Negi S; Shigematsu T
    Clin Calcium; 2010 Jul; 20(7):1096-102. PubMed ID: 20585189
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial.
    Sprague SM; Abboud H; Qiu P; Dauphin M; Zhang P; Finn W
    Clin J Am Soc Nephrol; 2009 Jan; 4(1):178-85. PubMed ID: 19056618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia.
    Shigematsu T;
    Clin Nephrol; 2008 Nov; 70(5):404-10. PubMed ID: 19000540
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A systematic review of the economic evaluations of non-calcium-containing phosphate binders, sevelamer and Lanthanum, in end-stage renal disease patients with hyperphosphatemia.
    Petrou P
    Expert Rev Pharmacoecon Outcomes Res; 2019 Jun; 19(3):287-298. PubMed ID: 30664365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland.
    Gutzwiller FS; Pfeil AM; Ademi Z; Blank PR; Braunhofer PG; Szucs TD; Schwenkglenks M
    Pharmacoeconomics; 2015 Dec; 33(12):1311-24. PubMed ID: 26334991
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the cost-utility of phosphate binders as a treatment option for hyperphosphatemia in chronic kidney disease patients: a systematic review and meta-analysis of the economic evaluations.
    Chaiyakittisopon K; Pattanaprateep O; Ruenroengbun N; Sapankaew T; Ingsathit A; Mckay GJ; Attia J; Thakkinstian A
    Eur J Health Econ; 2021 Jun; 22(4):571-584. PubMed ID: 33677736
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lanthanum carbonate provides control of phosphorus levels in patients new to phosphate binder therapy and patients changed from other phosphate binders.
    Noto L
    J Ren Nutr; 2011 May; 21(3):277-82. PubMed ID: 20598905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of lanthanum carbonate on phosphate control in continuous ambulatory peritoneal dialysis patients in Korea: a randomized prospective study.
    Lee YK; Choi HY; Shin SK; Lee HY
    Clin Nephrol; 2013 Feb; 79(2):136-42. PubMed ID: 23211335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study.
    Ruggeri M; Bellasi A; Cipriani F; Molony D; Bell C; Russo D; Di Iorio B
    J Nephrol; 2015 Oct; 28(5):593-602. PubMed ID: 25027030
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects and safety of lanthanum carbonate in end stage renal disease patients with hyperphosphatemia: a meta-analysis--system review of lanthanum carbonate.
    Guo H; Zhang X; Tang S; Zhang S
    Ren Fail; 2013; 35(10):1455-64. PubMed ID: 23992043
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An open-label phase 2 trial to assess the efficacy, safety and pharmacokinetics of lanthanum carbonate in hyperphosphatemic children and adolescents with chronic kidney disease undergoing dialysis.
    Wasilewska A; Murray RA; Sundberg A; Uddin S; Achenbach H; Shavkin A; Szabó T; Vergani A; Umeh O
    BMC Nephrol; 2022 Mar; 23(1):84. PubMed ID: 35236302
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparative study of 2 new phosphate binders (sevelamer and lanthanum carbonate) in routine clinical practice.
    Arenas MD; Rebollo P; Malek T; Moledous A; Gil MT; Alvarez-Ude F; Morales A; Cotilla E
    J Nephrol; 2010; 23(6):683-92. PubMed ID: 20540040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical effects of long-term (36-month) lanthanum carbonate administration in hemodialysis patients in Japan.
    Kishi Y; Obara Y; Hara K; Yamashiro H; Kurosawa N; Takada D
    Ther Apher Dial; 2014 Jun; 18 Suppl 1():9-13. PubMed ID: 24953760
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis.
    Huybrechts KF; Caro JJ; Wilson DA; O'Brien JA
    Value Health; 2005; 8(5):549-61. PubMed ID: 16176493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of lanthanum carbonate on metabolic acidosis in patients with chronic kidney disease stage IV, V and V-D.
    Beaubien-Souligny W; Bezzaoucha S; Pichette V; Lafrance JP; Bell R; Lamarche C; Ouimet D; Vallee M
    Int Urol Nephrol; 2015 Jul; 47(7):1165-71. PubMed ID: 25982583
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Studies of the Various Chronic Kidney Failure Rat Models and Hemodialysis Mini-pig Model for the Evaluation of Anti-hyperphosphatemia Drugs].
    Okabe T; Katoh M; Kano M; Okazaki R; Tanaka Y; Toyoda H; Ueno M
    Yakugaku Zasshi; 2019; 139(11):1435-1448. PubMed ID: 31685740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.